Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00942968 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
A Phase 4 study of Cancer, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 338
- Enrollment target
- 20
- Study locations
NCT00942968 is a Phase 4 study of Cancer that has completed, run by Pfizer. The registered enrollment target is 338 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT00942968, a Phase 4 study of Cancer, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 338 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the long term tolerability and safety of dalteparin in subjects with cancer.
Conditions Studied
Interventions
- DRUG dalteparin
Study Locations (20)
California
- Bay Area Cancer Research Group - Pleasant Hill
- Harbor-UCLA Medical Center - Torrance
Connecticut
- University of CT Health Center - Farmington
- Eastern Connecticut Hematology and Oncology Associates - Norwich
New York
- University of Rochester Medical Center - Rochester
- Stony Brook University, Medical Center - Stony Brook
Arizona
- Arizona Cancer Center - Tucson
District of Columbia
- Georgetown University Hospital-Lombardi Cancer Ctr - Washington D.C.
Florida
- Halifax Health - Daytona Beach
Georgia
- Atlanta Institute for Medical Research - Decatur
Illinois
- Orchard Healthcare Research Inc. - Skokie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2009-06 |
| Est. Completion | 2013-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00942968
The ClinicalTrials.gov registry entry for NCT00942968 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 338 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which dalteparin is the first listed.
NCT00942968 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Connecticut, New York.
Frequently Asked Questions
What is clinical trial NCT00942968 about?
NCT00942968 is a clinical study titled "Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer". The purpose of this study is to determine the long term tolerability and safety of dalteparin in subjects with cancer.
What is the current status of trial NCT00942968?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 338 participants. The study started on 2009-06. Estimated completion is 2013-06.
What conditions does trial NCT00942968 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT00942968?
The interventions under investigation include: dalteparin (DRUG).
Who is sponsoring clinical trial NCT00942968?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00942968 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The STOP-MED CTRCD Trial
RECRUITING · Phase 4
-
Tobacco Treatment Comparison for Cancer Care
COMPLETED · Phase 4
-
Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer
COMPLETED · Phase 4
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.